A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.

Trial Details

NCT ID

NCT07188558

Phase

PHASE3

Sponsor

Lyell Immunopharma, Inc.

Status

RECRUITING

Cancer Type

Non-Hodgkin Lymphoma Lymphoma

Interventions

rondecabtagene autoleucel
axicabtagene ciloleucel
lisocabtagene maraleucel

Locations (sample)

Gilbert, Arizona, United States|33.35283,-111.78903
Scottsdale, Arizona, United States|33.50921,-111.89903
Scottsdale, Arizona, United States|33.50921,-111.89903
Little Rock, Arkansas, United States|34.74648,-92.28959
Los Angeles, California, United States|34.05223,-118.24368

Key Eligibility Criteria

CAR T cell naïve and eligible to receive a CD19 CART-cell therapy
Histologically confirmed large B-cell lymphoma, including the following types defined by (WHO 2022) or International Consensus Classification (2022)
Diffuse large B-cell lymphoma (DLBCL)
Transformations of indolent B-cell lymphomas (excluding Richter's transformation)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →